Mediterranean Diet May Modestly Reduce Risk for Obesity-Related Cancers
By Lori Solomon HealthDay Reporter
THURSDAY, Feb. 27, 2025 -- Higher adherence to the Mediterranean diet (MedDiet) is associated with a modest reduction in the risk for obesity-related cancers (ORCs), according to a study published online Feb. 25 in JAMA Network Open.
Inmaculada Aguilera-Buenosvinos, Ph.D., from the University of Navarra in Spain, and colleagues examined the association between adherence to the MedDiet and the risk for ORCs. The analysis included data from 450,111 participants (mean age, 51.1 years) in the European Prospective Investigation Into Cancer and Nutrition study.
The researchers found that during a median 14.9 years of follow-up, 4.9 percent of participants experienced an ORC (rates, 0.053, 0.049, and 0.043 per person-year in the low, medium, and high MedDiet adherence groups, respectively). Compared with low MedDiet adherence (0 to 3 points), participants with high adherence to the MedDiet (7 to 9 points) had a lower risk for ORC (hazard ratio, 0.94). A similar inverse association was seen for participants with medium adherence (4 to 6 points) compared with low adherence.
"Our mediation analysis did not show waist-to-hip ratio or body mass index as mediators between MedDiet and ORC risk, possibly due to the low prevalence of obesity in our cohort and the distinct contribution of general versus abdominal obesity to metabolic disruptions," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Disparities Evident in Treatment, Survival for Patients With Pancreatic Cancer
THURSDAY, April 17, 2025 -- Among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), racial and ethnic minority patients and socially vulnerable populations are...
Tirzepatide Dispensations Increased Rapidly After Approval
TUESDAY, April 15, 2025 -- After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among...
Adverse Events From Semaglutide Seen in the ED Usually GI-Related
TUESDAY, April 15, 2025 -- The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.